Biological therapies in primary Sjögren's syndrome

Bibliography

• Bowman SJ, Ibrahim GH, Holmes G, Estimating the prevalence among Caucasian women of primary Sjogren's syndrome in two general practices in Birmingham, UK. Scand J Rheumatol 2004;33:39-43
   PubMed Web of Science ®Google Scholar
• Callaghan R, Prabu A, Allan RB, Direct healthcare costs and predictors of costs in patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2007;46:105-111
   PubMed Web of Science ®Google Scholar
• Bowman SJ, St Pierre Y, Sutcliffe N, Estimating indirect costs in primary Sjogren's syndrome. J Rheumatol 2010;11:1010-15
   Google Scholar
• Segal B, Bowman SJ, Fox PC, Primary Sjogren's syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes 2009;7:46
   PubMed Web of Science ®Google Scholar
• Christensen LB, Petersen PE, Thorn JJ, Schiodt M. Dental caries and dental health behavior of patients with primary Sjogren syndrome. Acta Odontol Scand 2001;59:116-20
   PubMed Web of Science ®Google Scholar
• Meijer JM, Meiners PM, Huddleston Slater JJ, Health-related quality of life, employment and disability in patients with Sjogren's syndrome. Rheumatology (Oxford) 2009;48:1077-82
   PubMed Web of Science ®Google Scholar
• Assistance Publique – Hopitaux de Paris. Hydroxychloroquine Versus Placebo in Primary Sjogren's Syndrome. ClinicalTrials.gov NCT00632866. Available from: http://clinicaltrials.gov/ct2/show/NCT00632866?term=NCT00632866&rank=1
   Google Scholar
• Fox PC, Datiles M, Atkinson JC, Prednisone and piroxicam for treatment of primary Sjogren's syndrome. Clin Exp Rheumatol 1993;11:149-56
   PubMed Web of Science ®Google Scholar
• Price EJ, Rigby SP, Clancy U, Venables PJ. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren's syndrome. J Rheumatol 1998;25:896-9
   PubMed Web of Science ®Google Scholar
• Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM. Methotrexate in primary Sjogren's syndrome. Clin Exp Rheumatol 1996;14:555-8
   PubMed Web of Science ®Google Scholar
• Drosos AA, Skopouli FN, Galanopoulou VK, Cyclosporin a therapy in patients with primary Sjogren's syndrome: results at one year. Scand J Rheumatol 1986;61:246-9
   Google Scholar
• van Woerkom JM, Kruize AA, Geenen R, Safety and efficacy of leflunomide in primary Sjogren's syndrome: a phase II pilot study. Ann Rheum Dis 2007;66:1026-32
   PubMed Web of Science ®Google Scholar
• Ng WF, Bowman SJ. Primary Sjogren's syndrome: too dry and too tired. Rheumatology (Oxford) 2010;49:844-53
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Tzioufas AG, Stone JH, Treatment of primary Sjogren syndrome: a systematic review. JAMA 2010;304:452-60
   PubMed Web of Science ®Google Scholar
• Voulgarelis M, Tzioufas AG. Pathogenetic mechanisms in the initiation and perpetuation of Sjogren's syndrome. Nat Rev Rheumatol 2010;6:529-37
   PubMed Web of Science ®Google Scholar
• Mariette X, Gottenberg JE. Pathogenesis of Sjogren's syndrome and therapeutic consequences. Curr Opin Rheumatol 2010;22:471-7
   PubMed Web of Science ®Google Scholar
• Mackay F, Woodcock SA, Lawton P, Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-710
   PubMed Web of Science ®Google Scholar
• Qian Y, Giltiay N, Xiao J, Deficiency of Act1, a critical modulator of B cell function, leads to development of Sjogren's syndrome. Eur J Immunol 2008;38:2219-28
   PubMed Web of Science ®Google Scholar
• Mariette X, Roux S, Zhang J, The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003;62:168-71
   PubMed Web of Science ®Google Scholar
• Pers JO, Daridon C, Devauchelle V, BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann NY Acad Sci 2005;1050:34-9
   PubMed Web of Science ®Google Scholar
• Jonsson MV, Szodoray P, Jellestad S, Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. J Clin Immunol 2005;25:189-201
   PubMed Web of Science ®Google Scholar
• Nossent JC, Lester S, Zahra D, Polymorphism in the 5′ regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjogren's syndrome. Rheumatology (Oxford) 2008;47:1311-16
   PubMed Web of Science ®Google Scholar
• Lavie F, Miceli-Richard C, Ittah M, B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjogren's syndrome. Scand J Immunol 2008;67:185-92
   PubMed Web of Science ®Google Scholar
• Szodoray P, Alex P, Jonsson MV, Distinct profiles of Sjogren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol 2005;117:168-76
   PubMed Web of Science ®Google Scholar
• Ittah M, Miceli-Richard C, Eric Gottenberg J, B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res Ther 2006;8(2):R51
   PubMed Web of Science ®Google Scholar
• Daridon C, Pers JO, Devauchelle V, Identification of transitional type II B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2006;54:2280-8
   PubMed Web of Science ®Google Scholar
• Katsifis GE, Rekka S, Moutsopoulos NM, Systemic and local interleukin-17 and linked cytokines associated with Sjogren's syndrome immunopathogenesis. Am J Pathol 2009;175:1167-77
   PubMed Web of Science ®Google Scholar
• Nguyen CQ, Hu MH, Li Y, Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjogren's syndrome: findings in humans and mice. Arthritis Rheum 2008;58:734-43
   PubMed Web of Science ®Google Scholar
• van Woerkom JM, Kruize AA, Wenting-van Wijk MJ, Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sjogren's syndrome compared with non-Sjogren's sicca syndrome. Ann Rheum Dis 2005;64:1474-9
   PubMed Web of Science ®Google Scholar
• Fox RI, Kang HI, Ando D, Cytokine mRNA expression in salivary gland biopsies of Sjogren's syndrome. J Immunol 1994;152:5532-9
   PubMed Web of Science ®Google Scholar
• Koarada S, Haruta Y, Mitamura M, Ex vivo CD+ T-cell cytokine expression from patients with Sjogren's syndrome following in vitro stimulation to induce proliferation. Rheumatology (Oxford) 2006;45:392-9
   PubMed Web of Science ®Google Scholar
• Kolkowski EC, Reth P, Pelusa F, Th1 predominance and perforin expression in minor salivary glands from patients with primary Sjogren's syndrome. J Autoimmun 1999;13:155-62
   PubMed Web of Science ®Google Scholar
• Prochorec-Sobieszek M, Wagner T, Loukas M, Histopathological and immunohistochemical analysis of lymphoid follicles in labial salivary glands in primary and secondary Sjogren's syndrome. Med Sci Monit 2004;10:BR115-21
   Google Scholar
• Adamson TC III, Fox RI, Frisman DM, Howell FV. Immunohistologic analysis of lymphoid infiltrates in primary Sjogren's syndrome using monoclonal antibodies. J Immunol 1983;130:203-8
   PubMed Web of Science ®Google Scholar
• Moutsopoulos HM, Hooks JJ, Chan CC, HLA-DR expression by labial minor salivary gland tissues in Sjogren's syndrome. Ann Rheum Dis 1986;45:677-83
   PubMed Web of Science ®Google Scholar
• Matthews JB, Deacon EM, Kitas GD, Primed and naive helper T cells in labial glands from patients with Sjogren's syndrome. Virchows Arch A Pathol Anat Histopathol 1991;419:191-7
   PubMedGoogle Scholar
• Matsumoto I, Okada S, Kuroda K, Single cell analysis of T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. Int J Mol Med 1999;4:519-27
   PubMed Web of Science ®Google Scholar
• Ajjan RA, McIntosh RS, Waterman EA, Analysis of the T-cell receptor Valpha repertoire and cytokine gene expression in Sjogren's syndrome. Br J Rheumatol 1998;37:179-85
   PubMedGoogle Scholar
• Yonaha F, Sumida T, Maeda T, Restricted junctional usage of T cell receptor V beta 2 and V beta 13 genes, which are overrepresented on infiltrating T cells in the lips of patients with Sjogren's syndrome. Arthritis Rheum 1992;35:1362-7
   PubMed Web of Science ®Google Scholar
• Ohyama Y, Nakamura S, Matsuzaki G, T-cell receptor Valpha and Vbeta gene use by infiltrating T cells in labial glands of patients with Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;79:730-7
   PubMed Web of Science ®Google Scholar
• Smith MD, Lamour A, Boylston A, Selective expression of V beta families by T cells in the blood and salivary gland infiltrate of patients with primary Sjogren's syndrome. J Rheumatol 1994;21:1832-7
   PubMed Web of Science ®Google Scholar
• Kay RA, Hay EM, Dyer PA, An abnormal T cell repertoire in hypergammaglobulinaemic primary Sjogren's syndrome. Clin Exp Immunol 1991;85:262-4
   PubMed Web of Science ®Google Scholar
• Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, Systemic increase in type I interferon activity in Sjogren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol 2008;38:2024-33
   PubMed Web of Science ®Google Scholar
• Emamian ES, Leon JM, Lessard CJ, Peripheral blood gene expression profiling in Sjogren's syndrome. Genes Immun 2009;10:285-96
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Cagnard N, Lucchesi C, Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA 2006;103:2770-5
   PubMed Web of Science ®Google Scholar
• Hjelmervik TO, Petersen K, Jonassen I, Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum 2005;52:1534-44
   PubMed Web of Science ®Google Scholar
• Korman BD, Alba MI, Le JM, Variant form of STAT4 is associated with primary Sjogren's syndrome. Genes Immun 2008;9:267-70
   PubMed Web of Science ®Google Scholar
• Miceli-Richard C, Comets E, Loiseau P, Association of an IRF5 gene functional polymorphism with Sjogren's syndrome. Arthritis Rheum 2007;56:3989-94
   PubMed Web of Science ®Google Scholar
• Nordmark G, Kristjansdottir G, Theander E, Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjogren's syndrome. Genes Immun 2009;10:68-76
   PubMed Web of Science ®Google Scholar
• Bave U, Nordmark G, Lovgren T, Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005;52:1185-95
   PubMed Web of Science ®Google Scholar
• Zheng L, Zhang Z, Yu C, Association between IFN-alpha and primary Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107:e12-18
   PubMed Web of Science ®Google Scholar
• Rowe D, Griffiths M, Stewart J, HLA class I and II, interferon, interleukin 2, and the interleukin 2 receptor expression on labial biopsy specimens from patients with Sjogren's syndrome. Ann Rheum Dis 1987;46:580-6
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Niewold TB, Moutsopoulos NM, Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept. Arthritis Rheum 2007;56:3995-4004
   PubMed Web of Science ®Google Scholar
• Lovgren T, Eloranta ML, Kastner B, Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjogren's syndrome autoantigen-associated RNA. Arthritis Rheum 2006;54:1917-27
   PubMed Web of Science ®Google Scholar
• Lavie F, Miceli-Richard C, Quillard J, Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J Pathol 2004;202:496-502
   PubMed Web of Science ®Google Scholar
• Ohlsson M, Szodoray P, Loro LL, CD40, CD154, Bax and Bcl-2 expression in Sjogren's syndrome salivary glands: a putative anti-apoptotic role during its effector phases. Scand J Immunol 2002;56:561-71
   PubMed Web of Science ®Google Scholar
• Kong L, Ogawa N, Nakabayashi T, Fas and Fas ligand expression in the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum 1997;40:87-97
   PubMed Web of Science ®Google Scholar
• Roescher N, Tak PP, Illei GG. Cytokines in Sjogren's syndrome: potential therapeutic targets. Ann Rheum Dis 2010;69:945-8
   PubMed Web of Science ®Google Scholar
• Wen CL, Wang CR, Chuang CY, Chen CY. Increased production of interleukin-6 and autoantibodies in patients with Sjogren's syndrome. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 1992;25:189-95
   PubMedGoogle Scholar
• Boumba D, Skopouli FN, Moutsopoulos HM. Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjogren's syndrome. Br J Rheumatol 1995;34:326-33
   PubMedGoogle Scholar
• De Vita S, Dolcetti R, Ferraccioli G, Local cytokine expression in the progression toward B cell malignancy in Sjogren's syndrome. J Rheumatol 1995;22:1674-80
   PubMed Web of Science ®Google Scholar
• Grisius MM, Bermudez DK, Fox PC. Salivary and serum interleukin 6 in primary Sjogren's syndrome. J Rheumatol 1997;24:1089-91
   PubMed Web of Science ®Google Scholar
• Garcic-Carrasco M, Font J, Filella X, Circulating levels of Th1/Th2 cytokines in patients with primary Sjogren's syndrome: correlation with clinical and immunological features. Clin Exp Rheumatol 2001;19:411-15
   PubMed Web of Science ®Google Scholar
• Szodoray P, Alex P, Brun JG, Circulating cytokines in primary Sjogren's syndrome determined by a multiplex cytokine array system. Scand J Immunol 2004;59:592-9
   PubMed Web of Science ®Google Scholar
• Giron-Gonzalez JA, Baturone R, Soto MJ, Implications of immunomodulatory interleukins for the hyperimmunoglobulinemia of Sjogren's syndrome. Cell Immunol 2009;259:56-60
   PubMed Web of Science ®Google Scholar
• Halse A, Tengner P, Wahren-Herlenius M, Increased frequency of cells secreting interleukin-6 and interleukin-10 in peripheral blood of patients with primary Sjogren's syndrome. Scand J Immunol 1999;49:533-8
   PubMed Web of Science ®Google Scholar
• Reksten TR, Jonsson MV, Szyszko EA, Cytokine and autoantibody profiling related to histopathological features in primary Sjogren's syndrome. Rheumatology (Oxford) 2009;48:1102-6
   PubMed Web of Science ®Google Scholar
• Bombardieri M, Barone F, Pittoni V, Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjogren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate. Arthritis Res Ther 2004;6:R447-56
   PubMed Web of Science ®Google Scholar
• Sakai A, Sugawara Y, Kuroishi T, Identification of IL-18 and Th17 cells in salivary glands of patients with Sjogren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol 2008;181:2898-906
   PubMed Web of Science ®Google Scholar
• Manoussakis MN, Boiu S, Korkolopoulou P, Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjogren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 2007;56:3977-88
   PubMed Web of Science ®Google Scholar
• Youinou P, Jamin C. The weight of interleukin-6 in B cell-related autoimmune disorders. J Autoimmun 2009;32:206-10
   PubMed Web of Science ®Google Scholar
• Vosters JL, Landek-Salgado MA, Yin H, Interleukin-12 induces salivary gland dysfunction in transgenic mice, providing a new model of Sjogren's syndrome. Arthritis Rheum 2009;60:3633-41
   PubMed Web of Science ®Google Scholar
• McCartney-Francis NL, Mizel DE, Redman RS, Autoimmune Sjogren's-like lesions in salivary glands of TGF-beta1-deficient mice are inhibited by adhesion-blocking peptides. J Immunol 1996;157:1306-112
   PubMed Web of Science ®Google Scholar
• McCartney-Francis NL, Mizel DE, Frazier-Jessen M, Lacrimal gland inflammation is responsible for ocular pathology in TGF-beta1 null mice. Am J Pathol 1997;151:1281-8
   PubMed Web of Science ®Google Scholar
• Stott DI, Hiepe F, Hummel M, Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren's syndrome. J Clin Invest 1998;102:938-46
   PubMed Web of Science ®Google Scholar
• Aziz KE, McCluskey PJ, Wakefield D. Characterisation of follicular dendritic cells in labial salivary glands of patients with primary Sjogren syndrome: comparison with tonsillar lymphoid follicles. Ann Rheum Dis 1997;56:140-3
   PubMed Web of Science ®Google Scholar
• Jonsson MV, Skarstein K, Jonsson R, Brun JG. Serological implications of germinal center-like structures in primary Sjogren's syndrome. J Rheumatol 2007;34:2044-9
   PubMed Web of Science ®Google Scholar
• Barone F, Bombardieri M, Manzo A, Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjogren's syndrome. Arthritis Rheum 2005;52:1773-84
   PubMed Web of Science ®Google Scholar
• Barone F, Bombardieri M, Rosado MM, CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J Immunol 2008;180:5130-40
   PubMed Web of Science ®Google Scholar
• Salomonsson S, Jonsson MV, Skarstein K, Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum 2003;48:3187-201
   PubMed Web of Science ®Google Scholar
• Amft N, Curnow SJ, Scheel-Toellner D, Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjogren's syndrome. Arthritis Rheum 2001;44:2633-41
   PubMed Web of Science ®Google Scholar
• Xanthou G, Polihronis M, Tzioufas AG, "Lymphoid" chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjogren's syndrome patients: possible participation in lymphoid structure formation. Arthritis Rheum 2001;44:408-18
   PubMed Web of Science ®Google Scholar
• Spachidou MP, Bourazopoulou E, Maratheftis CI, Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjogren's syndrome. Clin Exp Immunol 2007;147:497-503
   PubMed Web of Science ®Google Scholar
• Deshmukh US, Nandula SR, Thimmalapura PR, Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function. J Oral Pathol Med 2009;38:42-7
   PubMed Web of Science ®Google Scholar
• Kawakami A, Nakashima K, Tamai M, Toll-like receptor in salivary glands from patients with Sjogren's syndrome: functional analysis by human salivary gland cell line. J Rheumatol 2007;34:1019-26
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Demols P, Salmon I, Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis Rheum 2001;44:2371-5
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Demols P, Appelboom T. Infliximab in primary Sjogren's syndrome: one-year followup. Arthritis Rheum 2002;46:3301-3
   PubMed Web of Science ®Google Scholar
• Zandbelt MM, de Wilde P, van Damme P, Etanercept in the treatment of patients with primary Sjogren's syndrome: a pilot study. J Rheumatol 2004;31:96-101
   PubMed Web of Science ®Google Scholar
• Mariette X, Ravaud P, Steinfeld S, Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 2004;50(4):1270-6
   PubMed Web of Science ®Google Scholar
• Sankar V, Brennan MT, Kok MR, Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004;50:2240-5
   PubMed Web of Science ®Google Scholar
• Somer BG, Tsai DE, Downs L, Improvement in Sjogren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum 2003;49:394-8
   PubMed Web of Science ®Google Scholar
• Ring T, Kallenbach M, Praetorius J, Successful treatment of a patient with primary Sjogren's syndrome with Rituximab. Clin Rheumatol 2006;25:891-4
   PubMed Web of Science ®Google Scholar
• Pijpe J, van Imhoff GW, Vissink A, Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Ann Rheum Dis 2005;64:958-60
   PubMed Web of Science ®Google Scholar
• Pijpe J, van Imhoff GW, Spijkervet GW, Rituximab treatment in patients with primary Sjogren's syndrome: an open-label Phase II study. Arthritis Rheum 2005;52:2740-50
   PubMed Web of Science ®Google Scholar
• Pijpe J, Meijer JM, Bootsma H, Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjogren's syndrome. Arthritis Rheum 2009;60:3251-6
   PubMed Web of Science ®Google Scholar
• Meijer JM, Meiners PM, Vissink A, Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Guillevin L, Lambotte O, Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913-20
   PubMed Web of Science ®Google Scholar
• Seror R, Sordet C, Guillevin L, Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 2007;66:351-7
   PubMed Web of Science ®Google Scholar
• Ahmadi-Simab K, Lamprecht P, Nolle B, Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis 2005;64(7):1087-8
   PubMed Web of Science ®Google Scholar
• Voulgarelis M, Giannouli S, Tzioufas AG, Moutsopoulos HM. Long term remission of Sjogren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis 2006;65:1033-7
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Pennec Y, Morvan J, Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007;57:310-17
   PubMed Web of Science ®Google Scholar
• Dass S, Bowman SJ, Vital EM, Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008;67:1541-4
   PubMed Web of Science ®Google Scholar
• Shih WJ, Ghesani N, Hongming Z, F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome: before and after anti-CD20 antibody rituximab therapy. Clin Nucl Med 2002;27:142-3
   PubMed Web of Science ®Google Scholar
• Meijer JM, Pijpe J, Vissink A, Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis 2009;68:284-5
   PubMed Web of Science ®Google Scholar
• Voulgarelis M, Giannouli S, Anagnostou D, Tzioufas AG. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjogren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas. Rheumatology (Oxford) 2004;43:1050-3
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Fabris M, Salvin S, Controversies on rituximab therapy in sjogren syndrome-associated lymphoproliferation. Int J Rheumatol 2009;2009:424935
   PubMedGoogle Scholar
• Quartuccio L, Fabris M, Moretti M, Resistance to rituximab therapy and local BAFF overexpression in Sjogren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open Rheumatol J 2008;2:38-43
   PubMedGoogle Scholar
• Sanchez-Cano D, Callejas-Rubio JL, Lara-Jimenez MA, Successful use of rituximab in acquired C1 inhibitor deficiency secondary to Sjogren's syndrome. Lupus 2008;17:228-9
   PubMed Web of Science ®Google Scholar
• University Hospital, Brest. Tolerance and Efficacy of Rituximab in Sjogren's Disease. ClinicalTrials.gov NCT00740948. Available from: http://clinicaltrials.gov/ct2/show/NCT00740948?term=NCT00740948&rank=1
   Google Scholar
• Steinfeld SD, Tant L, Burmester GR, Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study. Arthritis Res Ther 2006;8:R129
   PubMed Web of Science ®Google Scholar
• Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjogren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined Phase III results. Arthritis Rheum 2003;49:585-93
   PubMed Web of Science ®Google Scholar
• Ferraccioli GF, Salaffi F, De Vita S, Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sjogren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine. Clin Exp Rheumatol 1996;14:367-71
   PubMed Web of Science ®Google Scholar
• Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjogren's syndrome. J Interferon Cytokine Res 1998;18:255-62
   PubMed Web of Science ®Google Scholar
• Ship JA, Fox PC, Michalek JE, Treatment of primary Sjogren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a Phase II clinical trial. IFN Protocol Study Group. J Interferon Cytokine Res 1999;19:943-51
   PubMed Web of Science ®Google Scholar
• Khurshudian AV. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:38-44
   PubMed Web of Science ®Google Scholar
• Yamada S, Mori K, Matsuo K, Interferon alfa treatment for Sjogren's syndrome associated neuropathy. J Neurol Neurosurg Psychiatry 2005;76:576-8
   PubMed Web of Science ®Google Scholar
• Unoki H, Moriyama A, Tabaru A, Development of Sjogren's syndrome during treatment with recombinant human interferon-alpha-2b for chronic hepatitis C. J Gastroenterol 1996;31:723-7
   PubMed Web of Science ®Google Scholar
• Moore PA, Belvedere O, Orr A, BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999;285:260-3
   PubMed Web of Science ®Google Scholar
• Schneider P, MacKay F, Steiner V, BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189:1747-56
   PubMed Web of Science ®Google Scholar
• Ittah M, Miceli-Richard C, Gottenberg JE, Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways. Eur J Immunol 2008;38:1058-64
   PubMed Web of Science ®Google Scholar
• Pers JO, Devauchelle V, Daridon C, BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheum 2007;56:1464-77
   PubMed Web of Science ®Google Scholar
• Lavie F, Miceli-Richard C, Ittah M, Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007;66:700-3
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Stohl W, Furie RA, A Phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61:1168-78
   PubMed Web of Science ®Google Scholar
• University of Udine. Efficacy and Safety of Belimumab in Primary Sjogren's Syndrome. ClinicalTrials.gov NCT01008982. Available from: http://clinicaltrials.gov/ct2/show/NCT01008982?term=NCT01008982&rank=1
   Google Scholar
• Assistance Publique – Hopitaux de Paris. Efficacy and Safety of Belimumab in Subjects With Primary Sjogren's Syndrome. ClinicalTrials.gov NCT01160666. Available from: http://clinicaltrials.gov/ct2/show/NCT01160666?term=NCT01160666&rank=1
   Google Scholar
• Bracewell C, Isaacs JD, Emery P, Ng WF. Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2009;9:909-19
   PubMed Web of Science ®Google Scholar
• Pena-Rossi C, Nasonov E, Stanislav M, An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 2009;18:547-55
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Papp K, Maari C, A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. J Am Acad Dermatol 2010;62:427-36
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009;68:1580-4
   PubMed Web of Science ®Google Scholar
• Helse Stavanger HF. Fatigue and Interleukin-1 (IL-1) Blockade in Primary Sjøgrens Syndrome. ClinicalTrials.gov NCT00683345. Available from: http://clinicaltrials.gov/ct2/show/NCT00683345?term=NCT00683345&rank=1
   Google Scholar
• Westhovens R, Kremer JM, Moreland LW, Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended Phase IIB study. J Rheumatol 2009;36:736742
   Google Scholar
• Goules A, Tzioufas AG, Manousakis MN, Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J Autoimmun 2006;26:165-71
   PubMed Web of Science ®Google Scholar
• Dimitriou ID, Kapsogeorgou EK, Moutsopoulos HM, Manoussakis MN. CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sjogren's syndrome patients indicating their intrinsic activation. Clin Exp Immunol 2002;127:386-92
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Furie R, Manzi S, A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003;48:719-27
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Davis JC Jr, Merrill JT, Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:3251-8
   PubMed Web of Science ®Google Scholar
• Aziz KE, McCluskey PJ, Wakefield D. Expression of selectins (CD62 E,L,P) and cellular adhesion molecules in primary Sjogren's syndrome: questions to immunoregulation. Clin Immunol Immunopathol 1996;80:55-66
   PubMedGoogle Scholar
• Turkcapar N, Sak SD, Saatci M, Vasculitis and expression of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and E-selectin in salivary glands of patients with Sjogren's syndrome. J Rheumatol 2005;32:1063-70
   PubMed Web of Science ®Google Scholar
• Mikulowska-Mennis A, Xu B, Berberian JM, Michie SA. Lymphocyte migration to inflamed lacrimal glands is mediated by vascular cell adhesion molecule-1/alpha4beta1 integrin, peripheral node addressin/l-selectin, and lymphocyte function-associated antigen-1 adhesion pathways. Am J Pathol 2001;159:671-81
   PubMed Web of Science ®Google Scholar
• Cauli A, Yanni G, Pitzalis C, Cytokine and adhesion molecule expression in the minor salivary glands of patients with Sjogren's syndrome and chronic sialoadenitis. Ann Rheum Dis 1995;54:209-15
   PubMed Web of Science ®Google Scholar
• National Institute of Dental and Craniofacial Research (NIDCR). Raptiva to Treat Sjogren's Syndrome. ClinicalTrials.gov NCT00344448. Available from: http://clinicaltrials.gov/ct2/show/NCT00344448?term=NCT00344448&rank=1
   Google Scholar
• Nishiyama T, Mishima K, Obara K, Amelioration of lacrimal gland inflammation by oral administration of K-13182 in Sjogren's syndrome model mice. Clin Exp Immunol 2007;149:586-95
   PubMed Web of Science ®Google Scholar
• Ng WF, Isaccs JD. From mice to men: the challenges of developing tolerance-inducing biological drugs for the clinic. In: Graca L, editor, The immune synapse as a novel target for therapy (progress in inflammation research). Birkhauser, Basel; 2008. p. 169-85
   Google Scholar
• Herold KC, Hagopian W, Auger JA, Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346(22):1692-8
   PubMed Web of Science ®Google Scholar
• Barrat FJ, Coffman RL. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev 2008;223:271-83
   PubMed Web of Science ®Google Scholar
• Proudfoot AE, Power CA, Schwarz MK. Anti-chemokine small molecule drugs: a promising future? Expert Opin Investig Drugs 2010;19:345-55
   PubMed Web of Science ®Google Scholar
• Dixon WG, Hyrich KL, Watson KL, Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-8
   PubMed Web of Science ®Google Scholar
• Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009;68:25-32
   PubMed Web of Science ®Google Scholar
• Furst DE. Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum 2009;39:18-29
   PubMed Web of Science ®Google Scholar
• Morrison T. Ocrelizumab Hits Endpoint in RA Trial; Safety Questions Remain. BioWorld Today: published online 14 December 2009: Available from: http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=53000
   Google Scholar
• Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 2009;60:3761-5
   PubMed Web of Science ®Google Scholar
• Bowman SJ, Booth DA, Platts RG. Measurement of fatigue and discomfort in primary Sjogren's syndrome using a new questionnaire tool. Rheumatology (Oxford) 2004;43:758-64
   PubMed Web of Science ®Google Scholar
• Bowman SJ, Booth DA, Platts RG, Validation of the Sicca Symptoms Inventory for clinical studies of Sjogren's syndrome. J Rheumatol 2003;30:1259-66
   PubMed Web of Science ®Google Scholar
• Bowman SJ, Hamburger J, Richards A, Patient-reported outcomes in primary Sjogren's syndrome: comparison of the long and short versions of the Profile of Fatigue and Discomfort–Sicca Symptoms Inventory. Rheumatology (Oxford) 2009;48:140-3
   PubMed Web of Science ®Google Scholar
• Seror R, Ravaud P, Bowman SJ, EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 2010;69:1103-9
   PubMed Web of Science ®Google Scholar
• Vitali C, Palombi G, Baldini C, Sjogren's syndrome disease damage index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjogren's syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum 2007;56:2223-31
   PubMed Web of Science ®Google Scholar
• Bowman SJ, Sutcliffe N, Isenberg DA, Sjogren's Systemic Clinical Activity Index (SCAI)–a systemic disease activity measure for use in clinical trials in primary Sjogren's syndrome. Rheumatology (Oxford) 2007;46:1845-51
   PubMed Web of Science ®Google Scholar
• Barry RJ, Sutcliffe N, Isenberg DA, The Sjogren's syndrome damage index – a damage index for use in clinical trials and observational studies in primary Sjogren's syndrome. Rheumatology (Oxford) 2008;47:1193-8
   PubMed Web of Science ®Google Scholar
• Kalk WW, Vissink A, Spijkervet FK, Sialometry and sialochemistry: diagnostic tools for Sjogren's syndrome. Ann Rheum Dis 2001;60:1110-16
   PubMed Web of Science ®Google Scholar
• Kalk WW, Vissink A, Stegenga B, Sialometry and sialochemistry: a non-invasive approach for diagnosing Sjogren's syndrome. Ann Rheum Dis 2002;61:137-44
   PubMed Web of Science ®Google Scholar
• Pijpe J, Kalk WW, Bootsma H, Progression of salivary gland dysfunction in patients with Sjogren's syndrome. Ann Rheum Dis 2007;66:107-112
   PubMed Web of Science ®Google Scholar
• Hu S, Wang J, Meijer J, Salivary proteomic and genomic biomarkers for primary Sjogren's syndrome. Arthritis Rheum 2007;56:3588-600
   PubMed Web of Science ®Google Scholar
• Hu S, Gao K, Pollard R, Preclinical validation of salivary biomarkers for primary Sjogren's syndrome. Arthritis Care Res (Hoboken) 2010;62:1633-8
   PubMed Web of Science ®Google Scholar
• Hu S, Zhou M, Jiang J, Systems biology analysis of Sjogren's syndrome and mucosa-associated lymphoid tissue lymphoma in parotid glands. Arthritis Rheum 2009;60:81-92
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Cagnard N, Pers JO, Gene expression profile in the salivary glands of primary Sjogren's syndrome patients before and after treatment with rituximab. Arthritis Rheum 2010;62:2262-71
   PubMed Web of Science ®Google Scholar
• Ng WF, Bowman SJ, Griffiths B. United Kingdom Primary Sjogren's Syndrome Registry – a united effort to tackle an orphan rheumatic disease. Rheumatology (Oxford) 2011;50:32-39
   PubMed Web of Science ®Google Scholar